Ergebnis der Suchanfrage nach @r@Borna@dokument

ONEKEY GmbH

Study: Final Push for the Cyber Resilience Act — Nearly Two-Thirds of Companies Still Unaware

Study: Final Push for the Cyber Resilience Act — Nearly Two-Thirds of Companies Still Unaware The new EU cybersecurity directive brings multiple challenges for companies, including reporting obligations, the creation of Software Bills of Materials, and the shift to “secure by design” products. ONEKEY IoT & OT ...

UCB

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...

DHL Group

PM: Neue U.S.-Zollvorschriften: Temporäre Einschränkungen beim postalischen Warenversand in die USA für Privat- und Geschäftskunden / PR: New U.S. customs regulations: Temporary restrictions on postal goods shipping to the U.S. for private an

Neue U.S.-Zollvorschriften: Temporäre Einschränkungen beim postalischen Warenversand in die USA für Privat- und Geschäftskunden - Executive Order „Suspending Duty-Free De Minimis Treatment for all Countries“ der USA ändern die Grundlagen für den postalischen Warenversand in die USA für alle Post- und ...

Ottobock SE & Co. KGaA

Ottobock with strong H1 2025 results

Infineon Technologies AG

Infineon strengthens startup ecosystem in India

LAUDA DR. R. WOBSER GMBH & CO. KG

3

LAUDA expands management responsibilities of Felix Heinrich-Bignasse and Enrico Bossart

Drees & Sommer SE

Drees & Sommer Designs Advanced Semiconductor R&D Facility for imec in Málaga

Technische Universität München

A new biotech hub for Munich

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE A new biotech hub for Munich Where science powers start-ups: Launching BioLabs|TUM • TUM Venture Labs cooperate with BioLabs and Lilly • 1,800 square meters of coworking lab space • Aiming at accelerating therapy development BioLabs, TUM Venture Labs, and Eli Lilly and Company (Lilly) today launched BioLabs|TUM, a new biotechnology innovation hub in central Munich. The initiative aims to empower early-stage biotech start-ups ...

Yanfeng

Yanfeng Unveils 2024 ESG Report: Driving Sustainability Forward

ONEKEY GmbH

New Automated Cybersecurity Testing for Embedded Software Available in Compliance with RED II EN18031 Standard

New Automated Cybersecurity Testing for Embedded Software Available in Compliance with RED II EN18031 Standard With the new simplified, automated testing process, embedded software can be checked within minutes for potential vulnerabilities and non-compliance with the RED II, EN 18031-1 directive. Düsseldorf, 23 ...

LAUDA DR. R. WOBSER GMBH & CO. KG

2

LAUDA earns silver medal from EcoVadis

PNO Innovation GmbH

TherVacB: Advance Curative Strategy for Chronic Hepatitis B

World Health Summit

World Health Summit 2025: Registration Open - First High-Level Speakers Announced

Berlin (ots) - Registration for the World Health Summit 2025 is now open. From October 12-14, Berlin will once again host one of the most important strategic global health gatherings worldwide. Under the theme "Taking Responsibility for Health in a Fragmenting World", the summit brings together leading minds from academia, politics, the private sector, and civil ...

XTEND

XTEND Secures $30M Extension to Complete $70M Series B to Scale Its Battle-Proven Autonomous AI Robots Across America

Tampa, Fla. (ots/PRNewswire) - Aliya Capital Partners and Protego Ventures Co-Lead Strategic Series B Round alongside participating investors: Len Blavatnik's Claltech, Union-Tech Ventures & Chartered Group, as XTEND's AI Robotic Technology Proves Itself in Global Conflicts and the Company Opens Its New U.S. ...

Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...

LTS Lohmann Therapie-Systeme AG

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Andernach / Montreal (ots) - LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality ...

Infineon Technologies AG

Tata Elxsi and Infineon Partner to Accelerate EV Innovation in India

PNO Innovation GmbH

Less than 30 days left to apply – don’t miss your chance

LAUDA DR. R. WOBSER GMBH & CO. KG

Norbert Hönninger celebrates 40 years with LAUDA

LAUDA DR. R. WOBSER GMBH & CO. KG

4

LAUDA Showcases AI Expertise in the SME Sector

GEA Group Aktiengesellschaft

2

Höchst Industrial Park: Carbon capture pilot plant goes into operation

hubergroup Deutschland GmbH

3

Press Release - hubergroup opens India’s first production facility for Direct Food Contact inks

ONEKEY GmbH

#1 Cyber Threat: Software Supply Chain Attacks Targeting Industry

#1 Cyber Threat: Software Supply Chain Attacks Targeting Industry The European Union Agency for Cybersecurity (ENISA) has identified software supply chain attacks as the top cyber threat – highlighting the urgent need to secure industrial IT and OT systems. The number of such incidents within the EU has more than doubled since 2020 Düsseldorf, 3 June 2025 – The German industrial sector is experiencing an increasing ...

BIAL SA

BIAL Announces Oral Presentation at GBA1 Meeting 2025

Porto, Portugal (ots/PRNewswire) - BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic ...